Prostatic neoplasms, castration-resistant
Clinical trials for Prostatic neoplasms, castration-resistant explained in plain language.
Never miss a new study
Get alerted when new Prostatic neoplasms, castration-resistant trials appear
Sign up with your email to follow new studies for Prostatic neoplasms, castration-resistant, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy combo shows promise for Hard-to-Treat prostate cancer
Disease control CompletedThis phase 2 trial tested two immunotherapy drugs, ipilimumab and nivolumab, in 69 men with a specific type of advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the combination could shrink tumors or slow disease progression. Participants…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase 2 • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
What drives survival in advanced prostate cancer? a brazilian study digs into patient data
Knowledge-focused CompletedThis study looks at medical records from 584 men in Brazil with castration-resistant metastatic prostate cancer, a form of the disease that no longer responds to hormone therapy. Researchers aim to describe how long these patients survive and to identify their individual characte…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Sponsor: Latin American Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Real-World data reveals how two prostate cancer drugs stack up
Knowledge-focused CompletedThis study looked at medical records from over 2,700 men with advanced prostate cancer that no longer responds to hormone therapy. Researchers compared two common treatments, enzalutamide and abiraterone, to see which one helped men live longer. The goal was to understand how the…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC